Form 4: UroGen Director Converts RSUs to Ordinary Shares

UroGen Pharma Ltd. Director Daniel George Wildman converted 2,000 Restricted Stock Units into ordinary shares on November 26, 2025.

Summary

• Daniel George Wildman, a Director of UroGen Pharma Ltd. (URGN), acquired 2,000 ordinary shares through the conversion of Restricted Stock Units (RSUs).
• The transaction occurred on November 26, 2025, with a deemed execution price of $0 for the RSU conversion.
• Following this transaction, Daniel George Wildman directly owns 2,000 ordinary shares.
• Additionally, Daniel George Wildman directly holds 6,000 derivative securities, specifically Restricted Stock Units, after the reported transaction.

Sentiment

Score: 6

Explanation: Routine conversion of Restricted Stock Units (RSUs) into ordinary shares by a director, increasing direct ownership, which is generally viewed as a minor positive for alignment.

Positives

• A Director increased their direct ownership of ordinary shares by 2,000, aligning management interests with shareholder interests.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the increase in direct ordinary share ownership by a director as a positive signal, indicating continued alignment of management's interests with those of the company's investors.

Key Dates

Recommendation

This Form 4 reports a routine conversion of Restricted Stock Units (RSUs) into ordinary shares by a director, which is a standard compensation event and does not provide new fundamental information to alter an investment thesis. Therefore, a 'hold' recommendation is appropriate as this event alone does not warrant a change in investment strategy.

Keywords

UroGen Pharma, URGN, Form 4, Insider Transaction, Restricted Stock Units, RSU conversion, Director ownership, equity compensation